Shigeki Ikushima
Nara-shi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.
Journal: Anticancer research
Published: May 24, 2026
Drug-related pressure ulcers in hospitalised patients: a multicentre retrospective study in Japan identifying high-risk medications and patient characteristics.
Journal: BMJ open
Published: December 11, 2025
Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: December 02, 2025
Neutrophil-to-lymphocyte ratio affects the impact of proton pump inhibitors on efficacy of immune checkpoint inhibitors in patients with non‑small-cell lung cancer.
Journal: International journal of clinical oncology
Published: March 05, 2025
Comparative inhibitory effects of bepotastine and diphenhydramine on rituximab-induced infusion reactions.
Journal: International journal of hematology
Published: February 03, 2025
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer.
Journal: Investigational new drugs
Published: December 29, 2023
Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study.
Journal: Biological & pharmaceutical bulletin
Published: May 31, 2023
Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients.
Journal: Anticancer research
Published: December 29, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026